WEIGHING IN: ACTUAL VS IDEAL VS ADJUSTED BODY WEIGTH TO CALCULATE DOSE OF MELPHALAN IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

被引：0
|
作者：
Kopp, Michelle [1 ]
Talamo, Giampaolo [1 ]
机构：
[1] Penn State Hershey Med Ctr, Hershey, PA USA
来源：
ONCOLOGY NURSING FORUM | 2015年 / 42卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
38
引用
收藏
页码：E155 / E155
页数：1
相关论文
共 50 条
  • [1] Effect of melphalan dose adjustment in multiple myeloma patients undergoing autologous stem cell transplantation
    Gonzalez, A. P.
    Gonzalez, A. J.
    Palomo, P.
    Fernandez, R.
    Pardo, C.
    Alarcon, C.
    Fonseca, A.
    Fonseca, A.
    Gonzalez, S.
    Rayon, C.
    Vallejo, C.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S228 - S229
  • [2] Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?
    Singh, V.
    Krishnamurthy, J.
    Duffey, S.
    Meagher, R.
    Villa, M.
    Monreal, J.
    Evens, A.
    Frankfurt, O.
    Altman, J.
    Gordon, L.
    Tallman, M.
    Williams, S.
    Winter, J.
    Singhal, S.
    Mehta, J.
    BONE MARROW TRANSPLANTATION, 2009, 43 (04) : 301 - 305
  • [3] Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?
    V Singh
    J Krishnamurthy
    S Duffey
    R Meagher
    M Villa
    J Monreal
    A Evens
    O Frankfurt
    J Altman
    L Gordon
    M Tallman
    S Williams
    J Winter
    S Singhal
    J Mehta
    Bone Marrow Transplantation, 2009, 43 : 301 - 305
  • [4] Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation
    Shultes, Kendall C.
    Arp, Christopher
    Stockerl-Goldstein, Keith
    Trinkaus, Kathryn
    DeFrates, Sean
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (04) : 687 - 693
  • [5] High-dose-Melphalan vs. Busulfan-Melphalan in patients with recurrent multiple myeloma after previous autologous stem cell transplantation
    Karp, S.
    Haenel, A.
    Herbst, R.
    Morgner, A.
    Thiel, A.
    Haenel, M.
    ONKOLOGIE, 2012, 35 : 146 - 146
  • [6] Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma
    Buadi, Francis K.
    Gertz, Morie A.
    Laplant, Betsy R.
    Halvorson, Alese
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Dingli, David
    Kapoor, Prashant
    Gonsalves, Wilson I.
    Miceli, Teresa
    Brandes, Eva
    Stafford, Scott L.
    Martenson, James A.
    Hogan, William J.
    Kumar, Shaji K.
    BLOOD, 2016, 128 (22)
  • [7] Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
    Srour, Samer A.
    Milton, Denai R.
    Bashir, Qaiser
    Nieto, Yago
    Saini, Neeraj
    Daher, May
    Ramdial, Jeremy
    Im, Jin
    Hosing, Chitra
    Delgado, Ruby
    Manasanch, Elisabet
    Lee, Hans C.
    Thomas, Sheeba
    Kaufman, Gregory
    Patel, Krina
    Popat, Uday
    Weber, Donna
    Orlowski, Robert
    Shpall, Elizabeth
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    HAEMATOLOGICA, 2021, 106 (12) : 3211 - 3214
  • [8] Matched pair analysis of intravenous busulfan and melphalan vs. melphalan alone as conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation
    de la Rubia, J.
    Lahuerta, J. J.
    Gonzalez, J. D.
    Ribas, P.
    Solano, C.
    Blade, J.
    San Miguel, J. F.
    Sanz, M. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 192 - 192
  • [9] Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
    Srour, Samer A.
    Milton, Denai
    Bashir, Qaiser
    Mehta, Rohtesh S.
    Delgado, Ruby
    Rondon, Gabriela
    Nieto, Yago
    Hosing, Chitra M.
    Popat, Uday R.
    Ciurea, Stefan O.
    Patel, Krina
    Lee, Hans C.
    Manasanch, Elisabet
    Thomas, Sheeba
    Weber, Donna
    Orlowski, Robert Z.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [10] Dose-Adjusted Melphalan Yields Comparable MRD-Negativity to Full-Dose Melphalan in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant
    Kort, Jeries
    Ignatz-Hoover, James
    Oley, Frank
    Cooper, Brenda
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S582 - S583
12345